A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Authors
Venugopal, BBaird, R
Kristeleit, R
Plummer, R
Cowan, Richard A
Stewart, A
Fourneau, N
Hellemans, P
Elsayed, Y
McClue, S
Smit, J
Forslund, A
Phelps, C
Camm, J
Evans, T
de Bono, J
Banerji, U
Affiliation
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow; The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust; UCL Cancer Institute; St. George's University of London, London; Northern Centre for Cancer Care, Freeman Hospital, Newcastle; The Christie NHS Foundation Trust, Manchester, United Kingdom; Janssen Research & Development, LLC, Beerse, Belgium; and Janssen Research & Development, LLC, Raritan, New Jersey.Issue Date
2013-08-01
Metadata
Show full item recordAbstract
To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetic and pharmacodynamic profile of quisinostat, a novel hydroxamate, pan-histone deacetylase inhibitor (HDACi).Citation
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. 2013, 19 (15):4262-72 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-13-0312PubMed ID
23741066Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-13-0312